New York, NY, United States of America

Ruimin Pan


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ruimin Pan: Innovator in Immunogenic Polypeptides

Introduction

Ruimin Pan is a notable inventor based in New York, NY (US). He has made significant contributions to the field of immunology through his innovative work on immunogenic polypeptides. His research focuses on the development of isolated immunogenic polypeptides and their applications in binding antibodies.

Latest Patents

Ruimin Pan holds a patent for his invention titled "Immunogenic Polypeptides." This patent describes isolated immunogenic polypeptides that include a scaffold polypeptide with a modified hairpin loop. The modification allows for the inclusion of one or more epitopes that are heterologous to the scaffold polypeptide. The scaffold polypeptide is designed to self-assemble with other scaffold polypeptides, forming a trimeric structure that mimics native pathogen epitopes. This structure is capable of binding antibodies that react to these native epitopes. Additionally, the patent covers an isolated immunogenic polypeptide that forms a pentameric structure, further enhancing its potential for immunological applications.

Career Highlights

Throughout his career, Ruimin Pan has worked with prestigious institutions, including New York University and Molsoft LLC. His work has been instrumental in advancing the understanding of immunogenic polypeptides and their potential uses in therapeutic applications.

Collaborations

Ruimin Pan has collaborated with notable colleagues, including Maxim Totrov and Xunqing Jiang. These collaborations have contributed to the development and refinement of his innovative research.

Conclusion

Ruimin Pan's contributions to the field of immunogenic polypeptides highlight his role as a significant inventor in the realm of immunology. His patented work demonstrates the potential for innovative solutions in the development of immunotherapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…